(State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Employer Identification No.) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Common Stock, par value $0.001 per share |
Exhibit No. | Description | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
ISOPLEXIS CORPORATION | ||||||||||||||
Date: March 2, 2022 | ||||||||||||||
By: | /s/ John Strahley | |||||||||||||
Name: | John Strahley | |||||||||||||
Title: | Chief Financial Officer |
Exhibit 99.1 |
Year ended December 31, | ||||||||||||||
(in thousands, except share and per share amounts) | 2021 | 2020 | ||||||||||||
Revenue | ||||||||||||||
Product revenue | $ | 16,201 | $ | 9,318 | ||||||||||
Service revenue | 1,057 | 1,069 | ||||||||||||
Total revenue | 17,258 | 10,387 | ||||||||||||
Cost of product revenue | 8,445 | 4,866 | ||||||||||||
Cost of service revenue | 47 | 108 | ||||||||||||
Gross profit | 8,766 | 5,413 | ||||||||||||
Operating expenses: | ||||||||||||||
Research and development expenses | 20,966 | 11,157 | ||||||||||||
General and administrative expenses | 26,349 | 8,023 | ||||||||||||
Sales and marketing expenses | 37,774 | 13,511 | ||||||||||||
Total operating expenses | 85,089 | 32,691 | ||||||||||||
Loss from operations | (76,323) | (27,278) | ||||||||||||
Other income (expense): | ||||||||||||||
Interest (expense), net | (3,618) | (18) | ||||||||||||
Other (expense) income, net | (1,628) | 4,032 | ||||||||||||
Net loss | $ | (81,569) | $ | (23,264) | ||||||||||
Accrued dividends on preferred stock | (10,455) | (6,137) | ||||||||||||
Net loss attributable to common stockholders | $ | (92,024) | $ | (29,401) | ||||||||||
Basic and diluted net loss per common share | $ | (8.99) | $ | (14.06) | ||||||||||
Weighted-average common shares outstanding—basic and diluted | 10,239,869 | 2,090,392 |
December 31, | ||||||||||||||
(in thousands, except share amounts) | 2021 | 2020 | ||||||||||||
Assets | ||||||||||||||
Current assets: | ||||||||||||||
Cash | $ | 126,566 | $ | 106,641 | ||||||||||
Accounts receivable, net | 4,100 | 2,922 | ||||||||||||
Inventories, net | 24,299 | 3,955 | ||||||||||||
Prepaid expenses and other current assets | 3,478 | 2,156 | ||||||||||||
Total current assets | 158,443 | 115,674 | ||||||||||||
Property and equipment, net | 5,778 | 3,227 | ||||||||||||
Intangible assets, net | 21,008 | 1,643 | ||||||||||||
Other assets | 2,243 | 3,061 | ||||||||||||
Total assets | $ | 187,472 | $ | 123,605 | ||||||||||
Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | ||||||||||||||
Current liabilities: | ||||||||||||||
Accounts payable | $ | 4,839 | $ | 2,137 | ||||||||||
Accrued expenses and other current liabilities | 7,827 | 2,129 | ||||||||||||
Deferred revenue | 915 | 356 | ||||||||||||
Total current liabilities | 13,581 | 4,622 | ||||||||||||
Warrant liability | — | 4,637 | ||||||||||||
Long-term debt | 31,646 | 22,137 | ||||||||||||
Total liabilities: | 45,227 | 31,396 | ||||||||||||
Commitments and Contingencies | ||||||||||||||
Redeemable convertible preferred stock, $0.001 par value, zero and 3,442,340 shares authorized at December 31, 2021 and 2020, respectively; zero and 3,211,652 shares issued and outstanding at December 31, 2021 and 2020, respectively | — | 143,460 | ||||||||||||
Stockholders’ deficit: | ||||||||||||||
Preferred stock, $0.001 par value; 20,000,000 and zero shares authorized at December 31, 2021 and 2020, respectively; and zero shares issued or outstanding | — | — | ||||||||||||
Common stock, $0.001 par value, 400,000,000 shares authorized; 39,036,010 and 2,133,904 shares issued and outstanding as of December 31, 2021 and 2020, respectively | 39 | 2 | ||||||||||||
Additional paid-in capital | 276,179 | 1,151 | ||||||||||||
Accumulated deficit | (133,973) | (52,404) | ||||||||||||
Total stockholders’ equity (deficit) | 142,245 | (51,251) | ||||||||||||
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $ | 187,472 | $ | 123,605 |
V%V*\$RU_=BK.WV^-%/-./'D43!H56TCS-_L-C8QVU-
MQ[V5N&/')\SQ,3^]=%23$S_8IA]Y:C#G/>H^]/4R]L4_#3F[Z4N"ZG=51\
M+PDL-(2==<,^ID K'4FAP>^K*&?G3VHKB[^[*=# F_W
M)O9CB74[ALJV&5;V9A[RK%><-1U\>_L@P[K@>]OFZQ& QOTFPNR82/C?EA]%
MCQN3]M.N4SYI$FX985<8MJ-B*^Q:G]:B'_+X;GT+@][Z-/J /NWEJ.,PY.6CD'V$V9PWZWRM\ G'1
M&5]\8J&6EZSXTRM_9D;1PX1_(L0K$&;/M=MZ%_";%&
9IPK1[Y'0(0@$!6 @BS67&OWJR;;36YS8'LD;M:
M@ TG:(I8[$6VH6(*7:K1-_4!2JZ]DS5MNB_+ZB?"[(4%:PK^JW71K033[DLO
M"CSZX\C"K*#PK2.]\]S=J$KX$P*J!$RT^:!5L'Z3')]MU+VI JPL\4\NH1SG
MSZ\,@9GL-I,BS=-?-K>O$_'8#"PR @$(0.#H!#3$CZ,S35'^5M"1MS;/.TI%
M?E,4>50?,5;,=XKZ)HUK IKV?7TWG2,(LSI
V=7P(C8'C\QK2?VTOET^=YCA'@U>.?'./
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M#489,@FYW2;MK7BI69B]K _W*H*5QEC>MF=W%[:@(5.@[B.0#V&[%2M_FHH8T4V9G%5=JD^3FN[K2UM(;= /?:W0O_>
M4M:Y:T/SH'5^>"Q3YP3J&C_MR9R+]N\O%+BWM8R7_%T*-6?@X^,E\QGBI%GN
MG,("H+(-=5S_\W_;GJG;RW[0)=M?Z7O[][=^ I78
Y.0@ "$(
M!" 0A (0@ $( !"$ A!0(X PJX:6A"$ 0A (0@ $( !"$
M A" 0@ $(3!- F)WFPE$(0 "$( !" 0A (0@ $( !"$ FH$
M$&;5T)(P!" 0A (0@ $( !"$ A" 0@ (%I @BSTUPX"@$(0 "
M$( !" 0A (0@ $( !"$! C0#"K!I:$H8 !" 0A (0@ $( !
M"$ A" 0@,$T 87::"T;"40A (0@ $( !"$ A" 0@ $(0 "
M:@009M70DC $( !"$ A" 0@ $(0 "$( !" @6D""+/37#@* 0A
M (0@ $( !"$ A" 0@ $(0$"- ,*L&EH2A@ $( !"$ A" 0@
M $(0 "$( !" P30!A=IH+1R$ 0A (0@ $( !"$ A" 0@ $(
MJ!% F%5#2\(0@ $( !"$ A" 0@ $(0 "$( !*8)(,Q.<^$H!"
M 0A (0@ $( !"$ A" 0@ $U @BS:FA)& (0@ $( !"$ A"
M 0@ $(0 "$(# - &$V6DN'(4 !" 0A (0@ $( !"$ A" 0@
MH$8 858-+0E# (0@ $( !"$ A" 0@ $(0 "$)@F@# [S86C$(
M!" 0A (0@ $( !"$ A" 34""#,JJ$E80A (0@ $( !"$
M A" 0@ $(0 "TP009J>Y.0@ "
M$( !" 0A (0@ $( !"$ A!0(X PJX:6A"$ 0A (0@ $( !
M"$ A" 0@ $(3!- F)WFPE$(0 "$( !" 0A (0@ $(.87&%
M 5;241!5 !"$ FH$$&;5T)(P!" 0A (0@ $( !"$ A" 0@
M (%I @BSTUPX"@$(0 "$( !" 0A (0@ $( !"$! C0#"K!I:$H8
M!" 0A (0@ $( !"$ A" 0@,$T 87::"T;"40A (0@ $( !
M"$ A" 0@ $(0 ":@009M70DC $( !"$ A" 0@ $(0 "$(
M!" @7D"MZ?']]+_YW/'+Q" 0@ $(0 "$( !" 0A (0@ $=DC@
M?^[=?TH*L[^=W%\[Q$J1( !"$ A" 0@ $(0 "$( !" 0C,$_CR
MA_OU]O1X+B7.RG8*\[GC%PA (0@ $( !"$ A" 0@ $(0 ".R7P
MY>2^%!%G'YS;*5**!0$(0 "$( !" 0A (0@ $( !"$!@G4 KSKJ7
M/"MGW0LK9=?KA#,@ $(0 "$( !" 0A (0@ $( "!@Q"0K0U$--7Z
L_^7._7(0E!03 A" 0@ $(0$")P/\'V*RM? ^R'.< 245.1*Y"8((!
end
Cover |
Mar. 02, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Mar. 02, 2022 |
Entity Registrant Name | IsoPlexis Corporation |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-40894 |
Entity Tax Identification Number | 46-2179799 |
Entity Address, Address Line One | 35 NE Industrial Road |
Entity Address, City or Town | Branford |
Entity Address, State or Province | CT |
Entity Address, Postal Zip Code | 06405 |
City Area Code | 203 |
Local Phone Number | 208-4111 |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | ISO |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Central Index Key | 0001615055 |
Amendment Flag | false |
=\0]\^"(G
MFC23%GNE.P1M]D.8C:81:#>,SG^JT7\7>*?2YR/I3\__^56.A&(?Q81]"4<\
M^*>E0"=4E(AD7S^HY-\"I!$^3;].S/2!=DC # &36@4%Q<,+%@GQEXTMBO92!82LJ>).6S5O0@*J@*
M/!YS-A"!B"C@ R8"F0KHZ@-%>(8I"$ 9(9:'S ?WSWZ